iovance biotherapeutics inc. - IOVA
IOVA
Close Chg Chg %
2.21 -0.01 -0.45%
Closed Market
2.20
-0.01 (0.45%)
Volume: 8.75M
Last Updated:
Dec 4, 2025, 4:00 PM EDT
Company Overview: iovance biotherapeutics inc. - IOVA
IOVA Key Data
| Open $2.20 | Day Range 2.16 - 2.24 |
| 52 Week Range 1.64 - 9.30 | Market Cap $877.30M |
| Shares Outstanding 396.97M | Public Float 333.04M |
| Beta 0.83 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.20 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 16.74M |
IOVA Performance
| 1 Week | -10.53% | ||
| 1 Month | -3.91% | ||
| 3 Months | -11.24% | ||
| 1 Year | -75.53% | ||
| 5 Years | -94.87% |
IOVA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
About iovance biotherapeutics inc. - IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
IOVA At a Glance
Iovance Biotherapeutics, Inc.
825 Industrial Road
San Carlos, California 94070
| Phone | 1-650-260-7120 | Revenue | 164.07M | |
| Industry | Biotechnology | Net Income | -372,177,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 13,698.991% | |
| Fiscal Year-end | 12 / 2025 | Employees | 838 | |
| View SEC Filings |
IOVA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.074 |
| Price to Book Ratio | 3.18 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.345 |
| Enterprise Value to Sales | 11.456 |
| Total Debt to Enterprise Value | 0.031 |
IOVA Efficiency
| Revenue/Employee | 195,787.589 |
| Income Per Employee | -444,125.298 |
| Receivables Turnover | 2.366 |
| Total Asset Turnover | 0.194 |
IOVA Liquidity
| Current Ratio | 3.736 |
| Quick Ratio | 3.314 |
| Cash Ratio | 2.647 |
IOVA Profitability
| Gross Margin | 10.77 |
| Operating Margin | -240.92 |
| Pretax Margin | -228.564 |
| Net Margin | -226.84 |
| Return on Assets | -44.024 |
| Return on Equity | -57.478 |
| Return on Total Capital | -48.419 |
| Return on Invested Capital | -52.848 |
IOVA Capital Structure
| Total Debt to Total Equity | 8.201 |
| Total Debt to Total Capital | 7.579 |
| Total Debt to Total Assets | 6.399 |
| Long-Term Debt to Equity | 6.386 |
| Long-Term Debt to Total Capital | 5.902 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Iovance Biotherapeutics Inc. - IOVA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 1.19M | 164.07M | - |
Sales Growth
| - | - | - | +13,698.99% | - |
Cost of Goods Sold (COGS) incl D&A
| 13.98M | 21.14M | 33.13M | 146.40M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 13.98M | 21.14M | 33.13M | 43.61M | |
Depreciation
| 13.98M | 21.14M | 23.28M | 22.40M | |
Amortization of Intangibles
| - | - | 9.85M | 21.20M | - |
COGS Growth
| +60.47% | +51.18% | +56.74% | +341.93% | |
Gross Income
| (13.98M) | (21.14M) | (31.94M) | 17.67M | |
Gross Income Growth
| -60.47% | -51.18% | -51.11% | +155.33% | |
Gross Profit Margin
| - | - | -2,686.12% | +10.77% | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 328.72M | 377.74M | 428.62M | 412.95M | |
Research & Development
| 259.04M | 294.78M | 344.08M | 282.34M | |
Other SG&A
| 69.68M | 82.96M | 84.54M | 130.61M | |
SGA Growth
| +29.81% | +14.91% | +13.47% | -3.66% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (342.70M) | (398.88M) | (460.56M) | (395.28M) | |
Non Operating Income/Expense
| 451.00K | 2.98M | 13.04M | 20.27M | |
Non-Operating Interest Income
| 451.00K | 2.98M | 13.04M | 20.27M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (342.25M) | (395.89M) | (447.52M) | (375.00M) | |
Pretax Income Growth
| -31.85% | -15.67% | -13.04% | +16.20% | |
Pretax Margin
| - | - | -37,638.02% | -228.56% | - |
Income Tax
| - | - | (3.48M) | (2.83M) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (342.25M) | (395.89M) | (444.04M) | (372.18M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (342.25M) | (395.89M) | (444.04M) | (372.18M) | |
Net Income Growth
| -31.85% | -15.67% | -12.16% | +16.18% | |
Net Margin Growth
| - | - | -37,345.42% | -226.84% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (342.25M) | (395.89M) | (444.04M) | (372.18M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (342.25M) | (395.89M) | (444.04M) | (372.18M) | |
EPS (Basic)
| -2.231 | -2.4858 | -1.8885 | -1.2839 | |
EPS (Basic) Growth
| -18.87% | -11.42% | +24.03% | +32.01% | |
Basic Shares Outstanding
| 153.41M | 159.26M | 235.13M | 289.88M | |
EPS (Diluted)
| -2.231 | -2.4858 | -1.8885 | -1.2839 | |
EPS (Diluted) Growth
| -18.87% | -11.42% | +24.03% | +32.01% | |
Diluted Shares Outstanding
| 153.41M | 159.26M | 235.13M | 289.88M | |
EBITDA
| (328.72M) | (377.74M) | (427.43M) | (351.67M) | |
EBITDA Growth
| -29.81% | -14.91% | -13.15% | +17.72% | |
EBITDA Margin
| - | - | -35,948.86% | -214.34% | - |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 7.75 | |
| Number of Ratings | 12 | Current Quarters Estimate | -0.163 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -1.071 | |
| Last Quarter’s Earnings | -0.25 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.28 | Next Fiscal Year Estimate | -0.599 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 6 | 10 | 10 |
| Mean Estimate | -0.16 | -0.15 | -1.07 | -0.60 |
| High Estimates | -0.08 | -0.14 | -0.99 | -0.41 |
| Low Estimate | -0.21 | -0.19 | -1.15 | -1.03 |
| Coefficient of Variance | -23.39 | -11.47 | -4.94 | -30.69 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Iovance Biotherapeutics Inc. - IOVA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Iovance Biotherapeutics Inc. - IOVA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Raj K. Puri Chief Regulatory Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Raj K. Puri Chief Regulatory Officer | 201,252 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.59 per share | 722,494.68 |
| Mar 21, 2025 | Raj K. Puri Chief Regulatory Officer | 203,761 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Igor P. Bilinsky Chief Operating Officer | 87,578 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.04 per share | 353,815.12 |
| Mar 6, 2025 | Friedrich Graf Finckenstein Chief Medical Officer | 70,317 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Friedrich Graf Finckenstein Chief Medical Officer | 15,626 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Friedrich Graf Finckenstein Chief Medical Officer | 92,913 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.04 per share | 375,368.52 |
| Mar 6, 2025 | Friedrich Graf Finckenstein Chief Medical Officer | 126,383 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Jean-Marc Bellemin Chief Financial Officer | 70,317 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Jean-Marc Bellemin Chief Financial Officer | 56,204 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.04 per share | 227,064.16 |
| Mar 6, 2025 | Jean-Marc Bellemin Chief Financial Officer | 87,938 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Frederick G. Vogt Interim CEO & General Counsel; Director | 333,350 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Frederick G. Vogt Interim CEO & General Counsel; Director | 41,669 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Frederick G. Vogt Interim CEO & General Counsel; Director | 349,646 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.04 per share | 1,412,569.84 |
| Mar 6, 2025 | Frederick G. Vogt Interim CEO & General Counsel; Director | 445,059 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Igor P. Bilinsky Chief Operating Officer | 70,317 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Igor P. Bilinsky Chief Operating Officer | 14,065 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Igor P. Bilinsky Chief Operating Officer | 120,880 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 13, 2025 | Dan Kirby Chief Commercial Officer | 35,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2025 | Dan Kirby Chief Commercial Officer | 120,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |